The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1611
November 16, 2020
View Complete Issue         Table of Contents 2019 
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
November 16, 2020 (Issue: 1611)
The FDA has approved two new drugs for treatment of previously-treated unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki (Enhertu – Daiichi-Sankyo/AstraZeneca), an...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
Article code: 1611e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.